

**Question for written answer E-005369/2013
to the Commission**
Rule 117
Horst Schnellhardt (PPE)

Subject: Animal by-products - chondroitin

Chondroitin, extracted from cartilage, is used for the medicinal and dietetic treatment of joint diseases. Regulation (EC) No 1069/2009 establishes an end point in the manufacturing chain for products which no longer have direct relevance for the safety of the feed chain. Products which have gone beyond the end point should be allowed to be placed on the market without restriction.

Does the Commission believe that chondroitin sulphate is a derived product, in accordance with the aforementioned Regulation, which has gone beyond the end point of the manufacturing chain, or must it be regarded as an animal by-product? For what reasons?